Amylyx PharmaceuticalsAMLX +5.41%33 Quick Ratio is 17.85 as of Mar. 2026, which is 145% above its 10-year median of 7.28. GuruFocus rates AMLX with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 997 Drug Manufacturers companies, Amylyx Pharmaceuticals ranks better than 97.59% on this metric.
Amylyx Pharmaceuticals has a quick ratio of 17.85. It generally indicates good short-term financial strength.
The historical rank and industry rank for Amylyx Pharmaceuticals's Quick Ratio or its related term are showing as below:
AMLX'
s Quick Ratio Range Over the Past 10 Years
Min: 0.71 Med: 7.28 Max: 17.85
Current: 17.85
During the past 7 years, Amylyx Pharmaceuticals's highest Quick Ratio was 17.85. The lowest was 0.71. And the median was 7.28.
AMLX's Quick Ratio is ranked better than 97.59% of 997
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs AMLX: 17.85
Amylyx Pharmaceuticals (NAS:AMLX) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Amylyx Pharmaceuticals Quick Ratio Related Terms
Amylyx Pharmaceuticals Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Amylyx Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amylyx Pharmaceuticals Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amylyx Pharmaceuticals's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Amylyx Pharmaceuticals's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Amylyx Pharmaceuticals's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amylyx Pharmaceuticals (AMLX) has a Quick Ratio of 17.85 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Amylyx Pharmaceuticals and its competitors. This is 145% above median its historical median of 7.28. Over the past decade, Amylyx Pharmaceuticals' Quick Ratio has ranged from 0.71 to 17.85. According to the industry distribution chart, Amylyx Pharmaceuticals ranks #24 out of 997 companies in the Drug Manufacturers industry, placing it in the top 2.4%.
Is Amylyx Pharmaceuticals' Quick Ratio too high?
Amylyx Pharmaceuticals' current Quick Ratio of 17.85 is 145% above median its 10-year median of 7.28. Over the past 10 years, this metric has ranged from a low of 0.71 to a high of 17.85. The Drug Manufacturers industry median Quick Ratio is 1.45. Amylyx Pharmaceuticals' value of 17.85 is 1131% above this industry median. Based on the distribution chart, Amylyx Pharmaceuticals ranks #24 out of 997 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Amylyx Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Amylyx Pharmaceuticals' Quick Ratio compare to PRGO and ANIP?
According to the Drug Manufacturers industry distribution chart, Amylyx Pharmaceuticals ranks #24 out of 997 companies for Quick Ratio. This places Amylyx Pharmaceuticals in the top 2% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 1.45. Amylyx Pharmaceuticals' value of 17.85 is 1131% above this benchmark. Historically, Amylyx Pharmaceuticals' own Quick Ratio has ranged from 0.71 to 17.85 over the past decade. While the company's 10-year median is 7.28 vs. the industry median of 1.45, Amylyx Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 997 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amylyx Pharmaceuticals's current Quick Ratio of 17.85 is 1131% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Amylyx Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amylyx Pharmaceuticals's current Quick Ratio is 17.85, which is 145% above median its own 10-year median of 7.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amylyx Pharmaceuticals stock overvalued right now?
Amylyx Pharmaceuticals (AMLX) has a current Quick Ratio of 17.85. The current Quick Ratio is 17.85, which is 145% above median its 10-year median of 7.28 and 1131% above the Drug Manufacturers industry median of 1.45. Amylyx Pharmaceuticals' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Amylyx Pharmaceuticals (AMLX), the current Quick Ratio is 17.85 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
33GF Score
Get the complete analysis for AMLX
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMLX has been successfully added to your 
